Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
For patients doing well on targeted therapies (alectinib, osimertinib) for metastatic NSCLC, what data / guidelines do you use to decide about holding treatment before/after surgical procedures?
Related Questions
How would you treat patient with a stage IV lung adenocarcinoma, an exon 21 p.H835L mutation, high TMB, and negative PD-L1?
For a patient with non-small cell lung cancer (NSCLC) harboring an EGFR or ALK mutation that transforms into small cell lung cancer (SCLC), would you add immunotherapy to chemotherapy or avoid immunotherapy given the tumor's EGFR/ALK origin?
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
Is concurrent immuno-radiation therapy a viable treatment option for patients with unresectable, non-metastatic, locally advanced lung cancer, who have high PD-L1 expression and no oncogenic mutations?
What is your approach to radiographically suspicious lung nodules for which initial biopsy was negative for malignancy?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
Would you consider adjuvant osimertinib for NSCLC with an EGFR E746_S752delinsV exon 19 mutation?
Would you consider using Elahere for patients with FOLR1-positive metastatic lung adenocarcinoma?
Which patients with metastatic NSCLC with an EGFR mutation would you treat with chemotherapy & osimertinib or amivantamab & lazertinib, and how would you choose between the two regimens?
Would you offer consolidative durvalumab after chemoRT for an isolated mediastinal recurrence of NSCLC that occurred during adjuvant pembrolizumab given for the initial lung cancer?
